Drug intelligence / Profile preview

VTS-63

Development stage: Unknown
Lead developer: Vitalis Pharma
Modality: Small Molecules
Administration: Oral

Overview

**VTS-63** is an oral fixed-dose combination candidate from Vitalis for dyslipidemia comprising extended-release niacin and a proprietary aspirin formulation known as VTS-Aspirin. The candidate is designed to retain niacin's lipid-modifying activity while reducing niacin-associated flushing through temporally controlled aspirin exposure. A small randomized crossover pilot study in healthy participants with niacin flushing reported fewer moderate or severe flushing events with VTS-63 than with niacin alone or standard aspirin administered concurrently with niacin.

Other names: ER-niacin + VTS-Aspirin

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HCAR2 (Hydroxycarboxylic acid receptor 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on VTS-63.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTS-63.

Explore the full profile